TIAZOLIDINEDIONAS PARA USO EN LA PREVENCIÓN O EL TRATAMIENTO DE CRECIMIENTO ÓSEO ANORMAL
EP3923937; US20220288044
The present invention refers to the use of thiazolidinediones (preferably rosiglitazone and/or pioglitazone) in the prevention or treatment abnormal bone growth selected from the list comprising: heterotopic ossification, osteophytes and/or syndesmophytes. According to the present invention, thiazolidinediones can be combined with corticoids and/or anti-inflammatory drugs (preferably non-steroidal anti-inflammatory drugs).

This new technology offers a disruptive approach to the blockade of the abonormal bone growth, through the inhibition of osteoblast differentiation and the promotion of the adipogenic one, which are opposing mechanisms. This can be implemented in clinical practice individually or in combination with present therapies. Currently there is no effective and non-aggressive treatments for these diseases. The use of bisphosphonates as prophylactics lacks evidence, surgical removal depends on certain factors, and radiotherapy is considered an aggressive and non-specific treatment. Certain antiinflammatory drugs have shown some effect in preventing HO. Nevertheless, these last medications to prevent HO only show partial results. Therefore, finding an effective and non-aggressive treatment to prevent the formation of heterotopic bone is a medical need, and our therapy accomplish these requisites.



.jpg)